ProMIS Neurosciences Company Leadership
| PMN Stock | USD 0.91 0.03 3.41% |
ProMIS Neurosciences' insiders are aggressively buying. The analysis of the overall insider sentiment regarding ProMIS Neurosciences suggests that virtually all insiders are extremely bullish. ProMIS Neurosciences employs about 7 people. The company is managed by 12 executives with a total tenure of roughly 17 years, averaging almost 1.0 years of service per executive, having 0.58 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2025-02-10 | Neil Cashman | Acquired 15000 @ 0.97 | View | ||
| 2024-09-23 | Madge K Shafmaster | Acquired 70000 @ 1.28 | View | ||
| 2024-09-20 | Madge K Shafmaster | Acquired 60000 @ 1.25 | View | ||
| 2024-08-14 | Patrick D Kirwin | Acquired 10000 @ 1.25 | View |
Monitoring ProMIS Neurosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. ProMIS Neurosciences Management Team Effectiveness
The company has Return on Asset of (1.2439) % which means that on every $100 spent on assets, it lost $1.2439. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.1956) %, meaning that it generated no profit with money invested by stockholders. ProMIS Neurosciences' management efficiency ratios could be used to measure how well ProMIS Neurosciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, ProMIS Neurosciences' Return On Tangible Assets are very stable compared to the past year. As of the 25th of July 2025, Return On Assets is likely to grow to 154.29, though Return On Capital Employed is likely to grow to (957.65). At this time, ProMIS Neurosciences' Return On Assets are very stable compared to the past year.As of the 25th of July 2025, Common Stock Shares Outstanding is likely to grow to about 27.8 M, while Net Loss is likely to drop (17.1 M).
ProMIS Neurosciences Workforce Comparison
ProMIS Neurosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 240. ProMIS Neurosciences holds roughly 7.0 in number of employees claiming about 2.92% of equities under Health Care industry.
ProMIS Neurosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProMIS Neurosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProMIS Neurosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ProMIS Neurosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ProMIS Neurosciences Notable Stakeholders
A ProMIS Neurosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ProMIS Neurosciences often face trade-offs trying to please all of them. ProMIS Neurosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ProMIS Neurosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Neil MD | CoChairman CoFounder | Profile | |
| Eugene Williams | CoFounder Chairman | Profile | |
| Neil MBA | Interim President | Profile | |
| Gail Farfel | Chief Officer | Profile | |
| Daniel MBA | Chief Officer | Profile | |
| Johanne Kaplan | Chief Officer | Profile | |
| Dennis Chen | Head Consultant | Profile | |
| David Wishart | Chief Officer | Profile | |
| MBA MBA | Chief Officer | Profile | |
| Gavin Malenfant | Chief Officer | Profile | |
| Ernest Bush | Head Consultant | Profile | |
| Larry MD | Chief Officer | Profile |
About ProMIS Neurosciences Management Performance
The success or failure of an entity such as ProMIS Neurosciences often depends on how effective the management is. ProMIS Neurosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ProMIS management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ProMIS management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 146.94 | 154.29 | |
| Return On Capital Employed | -1 K | -958 | |
| Return On Assets | 146.94 | 154.29 | |
| Return On Equity | 0.17 | 0.18 |
ProMIS Neurosciences Workforce Analysis
Traditionally, organizations such as ProMIS Neurosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ProMIS Neurosciences within its industry.ProMIS Neurosciences Manpower Efficiency
Return on ProMIS Neurosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Income Per Employee | 397K | |
| Net Income Per Executive | 231.6K | |
| Working Capital Per Employee | 2.4M | |
| Working Capital Per Executive | 1.4M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.